Summit Therapeutics Inc.
SMMT
Rang in aandelen
#1658
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aandeelprijs
$16.14
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$12.87B
Verandering (1 dag)
3.65%
Verandering (1 jaar)
-13.88%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Categorie
Healthcare
P/B-ratio voor Summit Therapeutics Inc. (SMMT)
P/B-ratio op October 2026 TTM: 18.69
Volgens de meest recente financiële rapporten en aandelenkoers van Summit Therapeutics Inc. is de huidige P/B-ratio (TTM) 18.69. Eind 2023 had het bedrijf een P/B-ratio van 20.82.
P/B-ratiohistoriek voor Summit Therapeutics Inc. van 2004 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 18.69 | -43.35% |
| 2024 | 32.99 | 58.49% |
| 2023 | 20.82 | 220.87% |
| 2022 | 6.49 | 117.76% |
| 2021 | 2.98 | -27.56% |
| 2020 | 4.11 | 536.54% |
| 2019 | 0.65 | -98.56% |
| 2018 | 45.00 | -138.35% |
| 2017 | -117.33 | -1,034.33% |
| 2016 | 12.56 | 5.70% |
| 2015 | 11.88 | -48.78% |
| 2014 | 23.20 | 2.85% |
| 2013 | 22.55 | 13.41% |
| 2012 | 19.89 | -52.35% |
| 2011 | 41.73 | 29.00% |
| 2010 | 32.35 | 6.43% |
| 2009 | 30.39 | 569.58% |
| 2008 | 4.54 | -3.53% |
| 2007 | 4.71 | -38.65% |
| 2006 | 7.67 | 60.25% |
| 2005 | 4.79 | -99.36% |
| 2004 | 747.02 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | -66.55% |
US
|
|
| 13.2547 | -29.08% |
US
|
|
| 4.208 | -77.48% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -66.92% |
NL
|
